Integrating genomics and proteomics-oriented biomarkers to comprehend lung cancer

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Lung cancer is the leading cause of cancer deaths worldwide. Recent years have brought tremendous progress in the development of genomic and proteomic platforms to study lung cancer progression and biomarker identification. Objective: To evaluate and integrate potential innovations of 'omics' (e.g., genomics and proteomics) technologies in dissecting biomarkers for lung cancer. Methods: Omics technologies permit simultaneous monitoring of many hundreds or thousands of macro and small molecules, as well as functional monitoring of multiple pivotal cellular pathways. Discussion follows to explore the principal challenges in the development of cancer biomarkers integrating genomics with proteomics data sets with their functional counterparts in conjunction with clinical data. Results/conclusion: Sets of genes and gene interactions affecting different subsets of cancers can be determined using genomics in lung cancer. Proteomic studies have generated numerous functional data sets of potential diagnostic, prognostic and therapeutic significance in lung cancer. It is likely that omics will take a central place in the understanding, diagnosis, monitoring and treatment of lung cancer. Here the potential benefits and pitfalls of these methodologies are reviewed for the faster discovery of therapeutically valuable biomarkers for lung cancer.

Original languageEnglish (US)
Pages (from-to)167-180
Number of pages14
JournalExpert Opinion on Medical Diagnostics
Volume3
Issue number2
DOIs
StatePublished - Mar 2009
Externally publishedYes

Fingerprint

Biomarkers
Genomics
Proteomics
Lung Neoplasms
Monitoring
Genes
Tumor Biomarkers
Macros
Technology
Innovation
Molecules
Cause of Death
Neoplasms

Keywords

  • Biomarkers
  • Genomics
  • Lung cancer
  • Omics
  • Proteomics
  • Small cell lung carcinoma

ASJC Scopus subject areas

  • Biomedical Engineering
  • Medicine(all)
  • Biochemistry, medical
  • Molecular Medicine

Cite this

Integrating genomics and proteomics-oriented biomarkers to comprehend lung cancer. / Nagathihalli, Nagaraj; Singh, Om V.

In: Expert Opinion on Medical Diagnostics, Vol. 3, No. 2, 03.2009, p. 167-180.

Research output: Contribution to journalArticle

@article{8e32b660d8d04ca99bdc7e3c06c506ff,
title = "Integrating genomics and proteomics-oriented biomarkers to comprehend lung cancer",
abstract = "Background: Lung cancer is the leading cause of cancer deaths worldwide. Recent years have brought tremendous progress in the development of genomic and proteomic platforms to study lung cancer progression and biomarker identification. Objective: To evaluate and integrate potential innovations of 'omics' (e.g., genomics and proteomics) technologies in dissecting biomarkers for lung cancer. Methods: Omics technologies permit simultaneous monitoring of many hundreds or thousands of macro and small molecules, as well as functional monitoring of multiple pivotal cellular pathways. Discussion follows to explore the principal challenges in the development of cancer biomarkers integrating genomics with proteomics data sets with their functional counterparts in conjunction with clinical data. Results/conclusion: Sets of genes and gene interactions affecting different subsets of cancers can be determined using genomics in lung cancer. Proteomic studies have generated numerous functional data sets of potential diagnostic, prognostic and therapeutic significance in lung cancer. It is likely that omics will take a central place in the understanding, diagnosis, monitoring and treatment of lung cancer. Here the potential benefits and pitfalls of these methodologies are reviewed for the faster discovery of therapeutically valuable biomarkers for lung cancer.",
keywords = "Biomarkers, Genomics, Lung cancer, Omics, Proteomics, Small cell lung carcinoma",
author = "Nagaraj Nagathihalli and Singh, {Om V.}",
year = "2009",
month = "3",
doi = "10.1517/17530050902725125",
language = "English (US)",
volume = "3",
pages = "167--180",
journal = "Expert Opinion on Medical Diagnostics",
issn = "1753-0059",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Integrating genomics and proteomics-oriented biomarkers to comprehend lung cancer

AU - Nagathihalli, Nagaraj

AU - Singh, Om V.

PY - 2009/3

Y1 - 2009/3

N2 - Background: Lung cancer is the leading cause of cancer deaths worldwide. Recent years have brought tremendous progress in the development of genomic and proteomic platforms to study lung cancer progression and biomarker identification. Objective: To evaluate and integrate potential innovations of 'omics' (e.g., genomics and proteomics) technologies in dissecting biomarkers for lung cancer. Methods: Omics technologies permit simultaneous monitoring of many hundreds or thousands of macro and small molecules, as well as functional monitoring of multiple pivotal cellular pathways. Discussion follows to explore the principal challenges in the development of cancer biomarkers integrating genomics with proteomics data sets with their functional counterparts in conjunction with clinical data. Results/conclusion: Sets of genes and gene interactions affecting different subsets of cancers can be determined using genomics in lung cancer. Proteomic studies have generated numerous functional data sets of potential diagnostic, prognostic and therapeutic significance in lung cancer. It is likely that omics will take a central place in the understanding, diagnosis, monitoring and treatment of lung cancer. Here the potential benefits and pitfalls of these methodologies are reviewed for the faster discovery of therapeutically valuable biomarkers for lung cancer.

AB - Background: Lung cancer is the leading cause of cancer deaths worldwide. Recent years have brought tremendous progress in the development of genomic and proteomic platforms to study lung cancer progression and biomarker identification. Objective: To evaluate and integrate potential innovations of 'omics' (e.g., genomics and proteomics) technologies in dissecting biomarkers for lung cancer. Methods: Omics technologies permit simultaneous monitoring of many hundreds or thousands of macro and small molecules, as well as functional monitoring of multiple pivotal cellular pathways. Discussion follows to explore the principal challenges in the development of cancer biomarkers integrating genomics with proteomics data sets with their functional counterparts in conjunction with clinical data. Results/conclusion: Sets of genes and gene interactions affecting different subsets of cancers can be determined using genomics in lung cancer. Proteomic studies have generated numerous functional data sets of potential diagnostic, prognostic and therapeutic significance in lung cancer. It is likely that omics will take a central place in the understanding, diagnosis, monitoring and treatment of lung cancer. Here the potential benefits and pitfalls of these methodologies are reviewed for the faster discovery of therapeutically valuable biomarkers for lung cancer.

KW - Biomarkers

KW - Genomics

KW - Lung cancer

KW - Omics

KW - Proteomics

KW - Small cell lung carcinoma

UR - http://www.scopus.com/inward/record.url?scp=77953453519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953453519&partnerID=8YFLogxK

U2 - 10.1517/17530050902725125

DO - 10.1517/17530050902725125

M3 - Article

C2 - 23485163

AN - SCOPUS:77953453519

VL - 3

SP - 167

EP - 180

JO - Expert Opinion on Medical Diagnostics

JF - Expert Opinion on Medical Diagnostics

SN - 1753-0059

IS - 2

ER -